Growth • Royalty Pharma
RPRX
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
4,5%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
-13,2%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-18,2%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-10,6%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-12%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
10,7%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!